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Introduction
Today, a number of different conditional mouse lines, which allows for in vivo regulation of expression of target gene(s) in specific cells, have been generated worldwide, and these mouse lines have been indispensable tools for recent research, including muscle-related research [1] . In these mouse lines, the Cre/loxP system was used to control target gene(s) with temporal and tissue/cell specific recombination. For example, in muscle research, paired box protein 7-CreER (Pax7  CreER ) mouse lines, which induce tamoxifen-mediated recombination, enable to trace lineages and/or to knock-out specific genes of muscle stem cells in postnatal muscles [2] [3] [4] . Also, muscle fiber specific conditional mouse lines, such as muscle creatine kinase-Cre (MCK Cre ), and myosin light chain 1-Cre (Myl1 Cre ) mice have provided important information in development, growth, and atrophy of muscle [5, 6] . However, the use of conditional mice has drawbacks, such as costs, breeding space, and animal welfare, in addition to its applicability in research. Induced pluripotent stem (iPS) cells, which were established initially in 2006 from mouse, and in 2007 from human, in theory could give rise to any type of cells except for extraembryonic tissues, such as trophoblasts [7] [8] [9] . Importantly, iPS cells are generated from somatic cells but not from embryos, indicating that iPS cells have much lower ethic hurdle than embryonic stem (ES) cells. As is the case with other types of cells, myogenic cells can be generated from both mouse and human iPS cells, although differentiation protocols for human iPS cells are more established than those for murine iPS cells [10] [11] [12] . Additionally, several types of muscle diseases have been modeled by iPS cell technology [13, 14] , suggesting that genetic mutations or modifications are transferred from patients with muscle diseases to iPSderived myogenic cells.
Here, I aimed to investigate whether iPS cells were able to be generated from tamoxifen-inducible Cre-driver mouse and to fine novel in vitro application of muscle specific conditional mouse. For this purpose, I generated iPS cells from myofiber specific conditional mouse, myogenic factor 6-CreER (Myf6 CreER ), with tamoxifen-inducible GFP expression [15] . Myf6, also known as MRF4, is a member of muscle regulatory factors (MRF) as well as MyoD and Myogenin, and its expression is known to be restricted in myofibers in postnatal muscle [16] . On the other hand, it has been reported that Myf6 was also expressed in muscle progenitors during embryogenesis, suggesting bimodality of Myf6 expression/function in myogenesis [17] [18] [19] . Here, I investigated using a bimodality of Myf6 expression whether muscle specific conditional mouse-derived iPS cells (mCM-iPSCs) can be available for muscle researches.
Materials and methods

Animals Myf6
CreERT2 (Myf6 CE ) and B6.Cg-Tg (CAG-cat,-EGFP) 39Miya (CAG-EGFP) mouse lines were provided by the Jackson Laboratory (Bar Harbor, ME, USA) and RIKEN BRC (Tsukuba, Ibaragi, Japan), respectively [15, 20] . These mice were crossed to generate Myf6 CE/wt ::CAG-EGFP mouse. Tamoxifen (1 mg/10 g body weight) was intraperitoneally injected for 5 days to induce Cre-mediated recombination. To check the presence of the recombination in skeletal muscle fibers, GFP signal was observed in dissected muscles, including tibialis anterior (TA), extensor digitorum longus (EDL), soleus, and heart of tamoxifen-injected mice using stereoscopic fluorescence microscopy. All mice were maintained, crossed, genotyped, and sacrificed in accordance with the Institutional Animal Care and Use Committee (IACUC) in the National Center for Geriatrics and Gerontology.
Isolation of tail fibroblasts
Mouse fibroblasts were isolated from tails of Myf6 CE/wt ::CAG-EGFP mouse (4-month old, male) according to a previous study [21] . Briefly, the mouse tail (about 3-cm) was dissected and cut into small pieces, following incubation in 70% ethanol for 5 min. Tail was digested in Collagenase D/Pronase (Roche, Basel, Switzerland) solution at 37°C for 90 min. Digested tail was washed with 10% fetal bovine serum (FBS)/ Roswell park memorial institute 1640 media (RPMI 1640) and then vigorously homogenized by pipetting. After removing digested tail tissue using a cell strainer, the homogenate was centrifuged and then the collected fibroblasts were plated onto collagen-coated cell culture dish. Fibroblasts were cultured until sub-confluent density.
Generation of iPS cell
To generate the iPS cell, tail fibroblasts from Myf6 CE/wt ::CAG-EGFP mouse were infected with Sendai-virus, carrying the human Oct4/ Sox2/Klf4/c-Myc (OSKM) genes, for 24 h (Cytotune 2.0; ID Pharma, Tokyo, Japan) [22] . Then, infected cells were seeded onto mouse embryonic fibroblasts (MEF) in GS2-M media, including LIF and 2i (Takara, Shiga, Japan). Presence of mCM-iPSC colonies were confirmed by Day 25 (P0 generation), and P5-7 generations of mCM-iPSCs were used for experiments in this study. The murine iPS cell, iPS-MEF-Ng-492B-4, was used as a control (RIKEN BRC).
Myogenic differentiation
To induce myogenic differentiation of mCM-iPSCs, the protocol using CHIR was applied (modified from Ref. [23] ) (see Fig. 2A ). Briefly, mCM-iPSCs were cultured in serum free differentiation media (SFD: 75% Iscove's modified Dulbecco's Media (IMDM)/25% F12/1% B27 (w/ o RA)/1% antibiotics/0.5% BSA/0.5% N2 supplement/0.45 mM Monothioglycerol/50 mg/ml Ascorbic acid) for 2 days in free floating condition. After 2 days, developed embryoid bodies were once trypsinized and then re-cultured in SFD media including 10 μM CHIR and 5 ng/ml VEGF (SFD + C + V). Embryoid bodies were further cultured for 2 days in Stemline (Sigma-Aldrich, St. Louis, MO, USA) media with 10 ng/ml bFGF (Stemline + F), and then plated onto collagen-coated cell culture dish. After additional 4 days in cultured with Stemline + F media, the media was replaced to 1% N2/F12/DMEM and cells were cultured for another 15-18 days. At day 7 or Day 14, tamoxifen (100 nM 4OH-TAM) was added into the media for 1 day to induce Cremediated GFP expression in Myf6 + cells.
RT-PCR
Total RNA was extracted from cells at Day 0, 4, 7, 9, 10, 11 of myogenic differentiation (n = 3 for each time point) and cDNA was synthesized using the SuperPrep II Cell Lysis Kit (TOYOBO, Osaka, Japan). Polymerase chain reaction was performed on the CFX96 RealTime PCR Detection System (Bio-Rad, Hercules, CA, USA) using the following primer sets: pax7; 5′-CTCAGTGAGTTCGATTAGCCG -3′ and 5′-AGACGGTTCCCTTTGTCGC -3′, myf5; 5′-TGAGGGAACAGGTGGAG AAC -3′ and 5′-AGCTGGACACGGAGCTTTTA -3′, myod; 5′-AGCACTA CAGTGGCGACTCA -3′ and 5′-GCTCCACTATGCTGGACAGG -3′, myf6; 5′-GGGCCTGGTGATAACTGCT -3′ and 5′-AGAAAGGCGCTGAAGACTG -3′, gapdh; 5′-GTGAAGGTCGGTGTGAACG -3′ and 5′-ATTTGATGTTA GTGGGGTCTCG -3′.
Immunocytochemistry
For immunocytochemistry, cells were cross-linked with 4% paraformaldehyde (PFA) for 15 min at room temperature. After washing with phosphate-buffered saline (PBS), cells were blocked with 4% normal goat serum/0.1% Tween 20/PBS for 1 h at room temperature and then incubated with primary antibodies. Primary antibodies used in this study were: anti-Pax7 (DSHB, Iowa City, IA, USA, 1:100), antiMyoD (5.5A; Santa Cruz, Carlsbad, CA, USA, 1:100), anti-Myogenin (F5D; Santa Cruz, 1:200), anti-Myosin Heavy Chain (MF20; eBioscience, San Diego, CA, USA, 1:100), anti-GFP (MBL, Nagoya, Aichi, Japan, 1:200), CD144 (VE-cadherin; 1:100, eBioscience), and Nanog (Reprocell, Yokohama, Kanagawa, Japan, 1:100). The secondary antibodies used in this study were: Alexa Fluor 488 or Alexa Fluor 594 goat anti-mouse IgG, and Alexa Fluor 488 goat anti-rabbit IgG (Abcam, Cambridge, UK), all used at a 1:400 dilution. DAPI in anti-fading reagent was used for nuclear staining.
Results
Generation of muscle specific conditional mouse-derived iPS cells
Myf6
CreERT2 mouse and CAG-EGFP mouse were crossed to generate Myf6 CE/wt ::CAG-EGFP mouse (Fig. 1A) . To confirm skeletal muscle specific recombination after tamoxifen injection, three different areas of skeletal muscles (TA, EDL, and Soleus) and heart were dissected and GFP expression was observed in vivo. Fluorescence signals were detected in both fast (TA and EDL) and slow (Soleus) muscles, while heart did not show any GFP signal (Fig. 1B) . Because Myf6 is generally expressed in both types of fibers in the postnatal muscle but not in heart [15] , these observations confirmed a limited Cre-mediated recombination in skeletal muscle. Next, I generated the iPS cell line from fibroblasts harvested from Myf6 CE/wt ::CAG-EGFP mouse tails. After transfection of conditional mouse-derived fibroblasts, cells were cultured in specific media including 2i, and iPS-like colonies were observed within 25 days (Fig. 1C) . Because these colonies expressed pluripotent stem cell markers, such as Nanog, I confirmed that these colonies were iPS cells and named the muscle specific conditional mouse-derived iPS cells as mCM-iPSCs. I also detected the two alleles, Myf6-CreER and GFP-floxed, in the genome of this mCM-iPSC (Fig. 1D ).
Myogenic differentiation capacity of mCM-iPSCs
Next, I investigated whether generated mCM-iPSCs possessed myogenic differentiation capacity. Myf6 CE/wt ::CAG-EGFP mouse-derived mCM-iPSCs were subjected to myogenic differentiation conditions, as described in a previous study [23] (Fig. 2A) . Under this culture condition, mCM-iPSCs gradually expressed muscle-related genes, such as myod, along with the time (Fig. 2B) , suggesting that mCM-iPSCs differentiated into myogenic cell lineages. Importantly, differentiated mCM-iPSCs expressed major markers for myogenic lineages even at the protein level. Particularly, the presence of multinucleated myotubes expressing myosin heavy chain indicated the myogenic differentiation capacity of mCM-iPSCs (Fig. 2C ).
Homologous recombination in mCM-iPSCs
As mentioned above, after Myf6 CE/wt ::CAG-EGFP mouse showed muscle specific reporter expression due to tamoxifen injection, I next investigated whether muscle specific Cre-recombination was induced in mCM-iPSCs from this mouse line. Tamoxifen was added into the culture at day 14 of myogenic differentiation, and then GFP expression in multinucleated myotubes was investigated at day 18 of myogenic differentiation (Fig. 3A) . As a result, almost all myotubes showed GFP reporter expression, indicating that tamoxifen-mediated Cre-recombination successfully induced recombination in mCM-iPSCs (Fig. 3B) . I also confirmed no GFP expression in Pax7 + muscle progenitor cells and in VE-cadherin + vascular endothelial-like cells (Fig. 3C ). Taken together, these results clearly demonstrated the specificity of Cre-recombination in mCM-iPSCs.
Application of mCM-iPSCs in tracing myogenesis
In this study, I investigated whether mCM-iPSCs were capable of inducing in vitro myogenesis using the lineage tracing technique. Briefly, iPS cells from Myf6 CE/wt ::CAG-EGFP mouse were subjected to myogenic differentiation, and then tamoxifen was added into the media at Day 7 of in vitro myogenesis, which is an earlier phase than Day 14 (Fig. 4A) . As a result, I detected GFP expression in MyoD + myoblasts and MHC + myotubes at Day 18, in addition to a GFP negative population in Pax7 + muscle progenitor cells, MyoD + myoblasts, and MHC + myotubes (Fig. 4B) . These results indicated that Myf6 was already expressed in an early phase of myogenesis, suggesting the 1 st wave of Myf6 expression (Fig. 4C) . 
Discussion
Established Myf6
CE/wt
::CAG-EGFP mouse-derived iPS-like cells revealed morphology similar to the typical murine iPS cells, and expression of pluripotent marker Nanog, indicating successful generation of iPS cells from conditional mouse using a regular protocol. However, the current protocol to generate iPS cell lines using tail fibroblasts is time consuming (~25 days to find iPS cell-like colonies); therefore, the development of a protocol that allows for faster results is required. To this end, we may shorten the time if peripheral blood mononuclear cells from Cre-driver mouse are used as source of iPS cells, because of the previously established protocol in human cells [24] . Generated mCM-iPSCs from Myf6 CE/wt ::CAG-EGFP mouse can give rise to myogenic lineages, including embryonic muscle progenitors, myoblasts, and multinucleated myotubes. This indicates that conditional mouse derived-iPS cells are available for in vitro muscle research in addition for conventional in vivo studies. Although other type of cells, such as vascular endothelial-like cells, were simultaneously generated with this modified protocol, it proved that Cre-recombination occurred specifically in Myf6 + myogenic lineages but not in other cell types. The protocol for myogenic lineages has not been fully established in murine iPS cells, in contrast to human cells [10, 11, 23, 25] , causing lower myogenic differentiation of mCM-iPSCs. To maximize mCM-iPSCs for muscle research, hereafter, we need to establish proper protocols to efficiently induce myogenic cells from murine iPS cells. Myf6 (MRF4) is highly expressed in postnatal skeletal muscle and also in embryonic muscle progenitors. During embryogenesis, Myf6 acts as one of determination factors for muscle identity and priming factor for adult muscle stem cells [17, 18] . In addition, Myf6 also negatively regulates postnatal muscle growth through repression of MEF2 transcriptional factor [26] . Thus, Myf6 functions in multi-aspects of the muscle development and growth. In this study, I focused on a bimodal expression pattern of Myf6 during embryogenesis as an indicator for mCM-iPSC's application. Judging from the gene expression profile, myogenic differentiation started from nearby Day 4-7 in this differentiation condition, and myf6 was highly expressed in a later stage of differentiation (Day 10~). Actually, tamoxifen pulse in the stage of differentiation resulted in GFP labeling in multinucleated myotubes. Because Pax7 + cells and other types of mononuclear cells did not show reporter expression, Cre-recombination was driven specifically in myf6-expressing myotubes. On the other hand, tamoxifen pulse in the early phase of myogenic differentiation resulted in GFP expression in MyoD + myoblasts but not in all cells, and this mosaic GFP expression pattern was also observed in MHC + myotubes. As mentioned above, Myf6 expression is bimodal during embryogenesis, which is called as 1 st wave and 2 nd wave [17] . Therefore, results in this study indicated the possibility that mCM-iPSCs precisely reproduced both waves in vitro during early and late myogenesis (Fig. 4C ). If this is correct, a lineage tracing embryonic muscle progenitors using mCM-iPSCs would provide novel information during mouse myogenesis, because this phenomenon has been observed only at an individual level. While, I also detected GFP − / Pax7 + cells after tamoxifen administration at an early stage of myogenesis. When it is considered with exception for recombination efficiency after tamoxifen administration, results in this study suggested that Pax7 + muscle progenitors emerged from the Myf6 (MRF4) -/Pax7 + pool, which have been argued in previous study [17] . Because an induction protocol for satellite cells from iPS cells has not been established neither in mouse nor in human, I could not track embryonic muscle progenitors to adult stem cells in this study. Although further investigations are needed in this regard, I believe that muscle development from embryo to adult including satellite cell formation would be fully reproducible by mCM-iPSC technology. As far as I know, this is the first study that generated an iPS cell line from tamoxifen-inducible muscle-specific conditional mouse, and I demonstrated its possible applicability for muscle research. Although only lineage tracing of Myf6 + cells during myogenesis was performed in this study, mCM-iPSC technology can be used to understand the molecular mechanisms of muscle development and diseases by using conditional knock-out mice.
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